SCHEMBL17845339

SCHEMBL17845339

Cc1nnc(-n2c(=O)[nH]c3cc(F)ccc32)o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRP O00591 11/20 0.60
▸ GABRD O14764 11/20 0.60
▸ GABRA1 P14867 11/20 0.60
▸ GABRB1 P18505 11/20 0.60
▸ GABRG2 P18507 11/20 0.60
▸ GABRB3 P28472 11/20 0.60
▸ GABRA5 P31644 11/20 0.60
▸ GABRA3 P34903 11/20 0.60
▸ GABRA2 P47869 11/20 0.60
▸ GABRB2 P47870 11/20 0.60
▸ GABRA4 P48169 11/20 0.60
▸ GABRE P78334 11/20 0.60
▸ GABRA6 Q16445 11/20 0.60
▸ GABRG1 Q8N1C3 11/20 0.60
▸ GABRG3 Q99928 11/20 0.60
▸ GABRQ Q9UN88 11/20 0.60
▸ PARG Q86W56 3/20 0.53
▸ DAO P14920 2/20 0.48
▸ GRIN1 Q05586 1/20 0.43
▸ GRIN2B Q13224 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17001626 0.86 GABRP (0.52) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15599478 0.84 LMNA (0.53) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15599483 0.81 PARG (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15599494 0.81 GABRP (0.57) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17001625 0.78 PARG (0.59) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL15599481 0.76 PARG (0.57) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL16997504 0.72 GABRP (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL21464280 0.71 HRH3 (0.48) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL16657379 0.71 DAO (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL17845509 0.70 PARG (1.00) PARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 — — US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 — — US disclosed
CN-112979631-B PARG inhibiting compounds 癌症研究科技有限公司 2024-09-20 — — CN disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 — — US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 — — US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 — — EP disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 — — EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 — — EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 — — EP disclosed
CN-112979631-A PARG inhibiting compounds 癌症研究科技有限公司 2021-06-18 — — CN disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 — — US disclosed
CN-107295799-B PARG inhibiting compounds 癌症研究科技有限公司 2021-03-16 — — CN disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 — — US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 — — US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 — — US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 — — US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 — — US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 — — EP disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 — — WO disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 GABRP 4461/4885GABRD 4825/4885GABRA1 4811/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 GABRP 4488/4885GABRD 4835/4885GABRA1 4813/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 GABRP 4488/4885GABRD 4835/4885GABRA1 4813/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 GABRP 4461/4885GABRD 4825/4885GABRA1 4811/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 GABRP 4488/4885GABRD 4835/4885GABRA1 4813/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 GABRP 4488/4885GABRD 4835/4885GABRA1 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback